| 公司名称： |
上海波以尔化工有限公司 |
| 联系电话： |
Mr Qiu 86-21-50182298(Domestic Market)Miss Xu 86-21-50180596(Abroad Market) |
| 产品介绍： |
英文名称:ZM 336372
CAS:208260-29-1
|
| 公司名称： |
百灵威科技有限公司 |
| 联系电话： |
400-666-7788 +86-10-82848833 |
| 产品介绍： |
英文名称:ZM 336372
CAS:208260-29-1
包装信息：2.5g,250Mg 备注：化学试剂、精细化学品、医药中间体、材料中间体 |
| 公司名称： |
武汉易泰科技有限公司上海分公司 |
| 联系电话： |
86-21-50328103 * 801、802、803、804 Mobile:18930552037 |
| 产品介绍： |
英文名称:ZM 336372;3-(DiMethylaMino)-N-[3-[(4-hydroxybenzoyl)-aMino]-4-Methylphenyl]benzaMide
CAS:208260-29-1
纯度：99% HPLC 包装信息：1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g |
| 公司名称： |
上海佰世凯化学科技有限公司 |
| 联系电话： |
+86(0)21-20908456 |
| 产品介绍： |
英文名称:ZM 336372
CAS:208260-29-1
备注：C14484 |
| 公司名称： |
上海源鼎化学科技有限公司 |
| 联系电话： |
+86 (21) 5772-1279，+86 (21) 6775-2378 |
| 产品介绍： |
英文名称:3-(diMethylaMino)-N-(3-(4-hydroxybenzaMido)-4-Methylphenyl)benzaMide
CAS:208260-29-1
纯度：98% 包装信息：10g, 1kg, on request |
|
| 中文名称: | ZM 336372 | | 中文同义词: | 3-(二甲基氨基)-N-[3-[(4-羟基苯甲酰基)氨基]-4-甲基苯基]苯甲酰胺 | | 英文名称: | ZM 336372 | | 英文同义词: | N-[5-(3-DIMETHYLAMINOBENZAMIDO)-2-METHYLPHENYL]-4-HYDROXYBENZAMIDE;ZM 336372;3-(DIMETHYLAMINO)-N-[3-[(4-HYDROXYBENZOYL)-AMINO]-4-METHYLPHENYL]BENZAMIDE;Zinc00581684;3-(diMethylaMino)-N-(3-(4-hydroxybenzaMido)-4-Methylphenyl)benzaMide;Benzamide, 3-(dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]-;ZM 336372 3-(Dimethylamino)-N-[3-[(4-hydroxybenzoyl)amino]-4-methylphenyl]benzamide | | CAS号: | 208260-29-1 | | 分子式: | C23H23N3O3 | | 分子量: | 389.45 | | EINECS号: | | | 相关类别: | Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;A potent and specific inhibitor of the protein kinase c-Raf.;MAPK |
| 生物活性 | ZM 336372是一种有效的，选择性的c-Raf抑制剂，IC50为70 nM，比作用于B-RAF选择性高10倍，对PKA/B/C， AMPK， p70S6等没有抑制作用。 | | 体外研究 | ZM 336372 shows 10-fold selectivity over B-Raf. ZM 336372 weakly inhibits SAPK2a/p38α and SAPK2b/p38β with IC50 of 2 μM, and is selective over 17 other protein kinases including PKA, PKC, AMPK, p42 MAPK, MKK1, SAPK1/JNK, and CDK1 even at the concentration of up to 50 μM. ZM 336372 does not prevent constitutive as well as growth factor or phorbol ester induced activation of MKKl or p42 MAPK/ERK2. Moreover, ZM 336372 dose not reverse the phenotype of Ras- or Raf-transformed cell lines. ZM 336372 treatment induces >100 activation of c-Raf and the B-Raf isoform, but it does not trigger any activation of MKKI or p42 MAPK/ERKP or induce any increase in the GTP-loading of Ras, suggesting that a feedback control loop exists by which Raf isoforms suppress their own activation, such that inhibition is always counterbalanced by reactivation. ZM 336372-induced activation of c-Raf is not prevented by inhibition of the MAPK cascade, protein kinase C or phosphatidylinositide 3-kinase. ZM 336372 (1 μM) abolishes the upregulation of eNOS after treatment with hydrogen peroxide. ZM 336372 treatment in carcinoid tumor cells results in progressive phosphorylation of Raf-1, mitogen-activated protein kinase 1/2, and extracellular signal-regulated kinase 1/2, and causes a significant reduction of bioactive hormone levels as well as the transcription factor, human achaete-scute homologue-1. Furthermore, ZM 336372 treatment leads to a marked suppression of cellular proliferation and induction of the cell cycle inhibitors p21 and p18. ZM 336372 inhibits the proliferation of pheochromocytoma cells, and suppresses NE vasoactive peptide production. ZM 336372 treatment in HepG2 induces the suppression of proliferation in a dose-dependent manner, suppression of hormone secretion, and up-regulation of cell cycle inhibitors. ZM 336372 also induces apoptosis in pancreatic adenocarcinoma cell lines by inhibiting glycogen synthase kinase-3β through phosphorylation of GSK-3β at Ser 9. |
|